Anti-tumor monoantino sing-off drug and small molecule-targeted drug is a hot spot in the development of domestic pharmaceutical enterprises.

Guide: Unlike the U.Smarket, Chinese companies, with the exception of Kingsley (Legendary Bio), do not have listed companies reporting cell therapy data, but the PD-1 monoab as the representative of the tumor immunology drugs accounted for a considerable number, and small molecule-targeted drugs chamber resistance!----In the previous 2020 ASCO Review (I): Cell therapy and small molecule-targeted drugs, we summarized 15 companies that rose more than 10 percent in the U.Sand Chinese open markets during this year's ASCO annual meetingsix of the companies reported positive data on cell therapy at the meeting, with Adaptimmune Therapeutics the biggest gainer, up 128 percent, and five others reporting results from small molecule-targeted drugsthe second review of the ASCO conference, the researchers will focus on the performance of domestic-listed pharmaceutical companies during ASCOdomestic capital markets are less sensitive to ASCO relative to US stocks, but there are still six domestic companies whose share prices rose by more than 10 per cent over the period of time (May 13-June 5) and between 9 and 10 per centunlike the U.Smarket, Chinese companies, with the exception of Kingsley (Legendary Bio), do not have listed companies reporting cell therapy data, but the PD-1 monoab represents a considerable number of oncology immunodrugs, and small molecule-targeted drugsnext, we analyzed and reviewed the six Chinese companies and the reported data that rose more than 10% before and after the ASCO meetingKeystone Pharmaceuticals: Licensing the introduction of drugs has helped the share price rise and partners reported clinical data on 3 drugs at the ASCO annual meeting, CS1001 is a full-length, full-length anti-PD-LIgG4 monoclonal anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-body anti-chip anti-chip anti-product developed by Ligand's OMT genetically modified animal platform after the cornerstone has been granted by Ligand in the United States, which reduces the risk of immunogenigenism and potential toxicity in patientsand both the drugs are from Blueprint Medicines, and Keystone Pharmaceuticals has acquired its interest in Chinain these data, blueprint's oral RET inhibitor pralsetinibI./II ARROW study is of particular concernRET gene fusion mutations and activation mutations are important tumor-driven gene variants in a number of cancers, such as non-small cell lung cancer (NSCLC) and thyroid cancer, and the data reported by Blueprint show strong anti-tumor activity and good safety in NSCLC and thyroid cancerBlueprint has filed a listing application with the FDA for PRalsetinib for RET fusion-positive NSCLC and thyroid cancer, and is expected to become the second listed RET inhibitor after Lilly Retevmo Keystone Pharmaceuticals is preparing to submit a domestic listing application in the second half of this year, and at the end of June with stone-burning medicine to reach an accompanying diagnostic cooperation Legendary Creatures: The cell therapy leader has successfully launched a successful U.S IPO of Kingsley's Legendary Creatures, which is dedicated to developing CAR-T therapy to fight cancer 2017, the company partnered with Janssen, a johnson-johnson company, to develop and promote its car-T treatment JNJ-4528 (LCAR-B38M), a targeted B-cell maturation antigen (BCMA) in December, the FDA awarded JNJ-4528 a breakthrough therapy for patients with multiple bone marrow cancer (MM) who had previously been treated at the ASCO annual meeting, Jansen revealed the latest data from a cartitude-1I.b/II clinical trial for drug treatment for recurrent/refractive MM patients data show that jNJ-4528 is remarkable this year's legendary creature spun off from Kingsley and officially listed on the Us stock market on June 5, offering $23 and raising $424 million the first day of listing, Legendary Bio jumped 61 per cent to a market capitalisation of $4,786m, or HK$37bn, surpassing the HONG Kong stock market value of parent company Kingsley by HK$36.4bn Cinda Bio: A number of antibody drugs are ready to be launched Cinda Bio is a domestic biopharmaceutical company dedicated to the development of innovative antibody drugs and other drugs at present, Cinda Bio has two products approved by the State Drug Administration (NMPA) for listing, namely PD-1 inhibitor Dabersu (Sindilli synth injection) and Bebarazumab biosimilar drug Daju Tong (IBI305) , five varieties entered Phase III clinical or critical clinical studies, and three single-resistant product selling applications were accepted by NMPA, two of which were included in the priority review declared clinical antibody drugs second only to Hengrui, ranking in the forefront of the country as ASCO annual meeting, Cinda Bio released positive data on Phase II critical studies on the treatment of a wide range of different cancers by Cindy Singli sing-it-ones, as well as research in conjunction with other antibody drugs Cindy's monotomare entered the National Health Insurance Directory last year to treat patients with at least second-line chemotherapy relapsed or refractive classic Hodgkin's lymphoma (cHL) announced in April that sales of the drug were about Rmb400m in the first quarter of this year , according to research and development statistics, there are currently more than 10 Cindy singli mitalyse research in progress, including other company listings and research in the research product co-use can be seen, Cinda Bio is actively developing new indications, and strive to improve the company's fist product sales Zhengda: Not only is It is imitation that Zhengda Qing is a controlling subsidiary of China Biopharma, a listed company in recent years, the Chinese market's "king of imitation" is no longer limited to imitation, active research and development of anti-tumor and other adaptive innovative drugs this asco annual meeting, Zheng Daqing also disclosed two research data on small molecule-targeted drugs TQB3602 is an oral protease inhibitor that is used in the treatment of multiple myeloma (MM) currently used in clinical protease inhibitors are the first generation of boratizomi and the second generation of Ishazomi TQ-B3101 is a tyrosine kinase inhibitor (TKI) targeting ALK, ROS1 and MET preclinical studies have shown that drugs have better inhibition and longer effects than gramethinib Junshi creature: Can PD-1 monophonos be catching up? Trepri monoabisis is the third approved pD-1 monoab, and the first approved PD-1 monoanti-resistiatis for domestic pharmaceutical companies is the company's only commercial product for Junshi Bio at ASCO's annual meeting, Junshi Bio disclosed data from several clinical trials of the drug but since the launch, The Ripley's sales have not been in a strong position compared with several other similar products listed and PD-1/PD-L1 monotoreactor is currently the domestic biotechnology companies research and development of ultra-hot target, the future will be more and more similar products approved to go public, competition will be extremely fierce , the company has submitted two new applications for treatment for peethopathic and nasopharyngeal cancers, which are expected to be approved in the near future according to the company's 2019 report, there are 30 monodrug and drug-based clinical trials around Trepri monoantines are actively developed, a wide range of melanoma, nasopharyngeal cancer, urinary skin cancer, breast cancer, lung cancer, liver cancer, esophageal cancer, kidney cancer, stomach cancer and other adaptations some small indications, such as sanybreast cancer, neuroendocrine tumors, etc are other competing companies have not been involved in, can avoid competition with similar products to a certain extent Kangfang Biology: The first product will soon be approved, established in 2012 Kangfang Bio focused on the development of innovative antibody drugs the company currently has 12 antibodies in clinical development at the ASCO annual meeting, the company disclosed the progress of clinical trials of two of the antibody drugs in April this year, Kangfang Bio was listed on the Hong Kong Stock Exchange It is one of Kang's strategies to and domestic and foreign pharmaceutical companies to actively carry out various forms of strategic cooperation 2015, the company will license Mercado with the antibody AK107 (MK-1308), which it has developed in its own, for $200 million 2019, it has established a partnership with Zhengda Tianqing and has established a joint venture company to jointly develop and commercialize its research and development of the PD-1 antibody drug Paapri monotophoid (AK105) In May , the two companies jointly submitted a new drug application for Penaprism (NDA) that was accepted by the National Drug Administration to treat patients with recurrent or refractive classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy , Paamprisa has conducted four registered trials in China for other indications (nasopharyngeal cancer, non-small cell lung cancer and liver cell cancer) and is expected to submit NDA within the next 1 to 2 years and under the previous cooperation agreement, the commercialization rights of Pai Amply mono-resisting are owned by the joint venture between the two parties References: 1 Companies' official websites.